Peter Langmuir

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Samuel A. Wells, Bruce G. Robinson, Robert F. Gagel et al. · Journal of Clinical Oncology · 2011 · 1.5K citations · Full text

Quantifying the Frequency of Alloreactive T Cells In Vivo: New Answers to an Old Question

Elliot J. Suchin, Peter Langmuir, Ed Palmer et al. · The Journal of Immunology · 2001 · 518 citations · Full text

Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease

Robert Zeiser, Nicola Polverelli, Ron Ram et al. · New England Journal of Medicine · 2021 · 453 citations · Full text

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

Roy S. Herbst, Yan Sun, Wilfried Eberhardt et al. · The Lancet Oncology · 2010 · 417 citations · Full text

Second-line Treatment, Oncology, Metronomic Therapy +10

Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Ronald B. Natale, Sumitra Thongprasert, F. Anthony Greco et al. · Journal of Clinical Oncology · 2011 · 296 citations